First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

被引：3

作者：

Yang, Shuang ^{[1
]}

Feng, Weineng ^{[1
]}

Deng, Yanming ^{[1
]}

Liang, Jianmiao ^{[1
]}

机构：

[1] First Peoples Hosp Foshan, Dept Head Neck & Thorac Oncol, Foshan, Peoples R China

来源：

WORLD JOURNAL OF SURGICAL ONCOLOGY | 2023年 / 21卷 / 01期

关键词：

Ensartinib; ALK rearranged; ALK I1171N; Lung caner;

D O I：

10.1186/s12957-023-02935-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance.Case presentationHere, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months.ConclusionsThis treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20.

引用

页数：4

共 50 条

[21] STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
Zhang, Linlin
Xiao, Ping
Meng, Fanlu
Zhong, Diansheng
CURRENT ONCOLOGY, 2022, 29 (10) : 6749 - 6753
[22] Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Devaraj, Suma
Panda, Soumya Surath
Arun, Gourab
Panda, Adya Kinkar
Mohapatra, Debahuti
Moharana, Lalatendu
Kolluri, Spoorthy
Kilaru, Sindhu
Mohanty, Swati Sucharita
Biswas, Ghanashyam
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2023,
[23] BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma A case report
Sui, Aixia
Song, Huiling
Li, Yitong
Guo, Litao
Wang, Kai
Yuan, Mingming
Chen, Rongrong
MEDICINE, 2021, 100 (08) : E24917
[24] Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
Li, Mengmeng
Xing, Ruyue
Huang, Jiuyan
Shi, Chao
Wei, Chunhua
Wang, Huijuan
FRONTIERS IN ONCOLOGY, 2023, 13
[25] Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
Hu, Han
Dai, Hui
Ding, Liren
TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2967 - 2972
[26] Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
Wen, Zhengqi
Xiong, Dun
Zhang, Shurong
Liu, Jiankun
Li, Bitao
Li, Raomei
Zhang, Hushan
FRONTIERS IN ONCOLOGY, 2021, 11
[27] First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
Majeed, Umair
Li, Shenduo
Seegobin, Karan
Nassar, Aziza
Manochakian, Rami
Zhao, Yujie
Lou, Yanyan
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (07):
[28] Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
Weidenbaum, Chloe
Cann, Christopher G.
Osmundson, Sarah
Iams, Wade T.
Osterman, Travis
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (08):
[29] Case Report: Response to ALK-TKIs in a metastatic lung cancer patient with morphological heterogeneity and consistent molecular features
Yang, Yu
Liu, Han
Liu, Tao-hua
Zheng, Xi-run
Wu, Bin
Zhou, Dong-jing
Zheng, Guang-juan
Chai, Xiao-shu
FRONTIERS IN ONCOLOGY, 2023, 13
[30] Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
Fan, Jun
Wu, Junhua
Huang, Bo
Zhu, Yili
Shi, Heshui
Dai, Xiaofang
Nie, Xiu
DIAGNOSTIC PATHOLOGY, 2020, 15 (01)

← 1 2 3 4 5 →